亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment

作者
Jingjing Lan,Yulan Qiu,Shuaijia Wang,Ying Zhang,Shiqi Cheng,Siying Chen,Yuanming Xing
出处
期刊:Frontiers in Cardiovascular Medicine [Frontiers Media]
卷期号:13: 1853767-1853767
标识
DOI:10.3389/fcvm.2026.1853767
摘要

Background: In multiple countries, clinical guidelines recommend proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lowering low-density lipoprotein cholesterol (LDL-C) in individuals with atherosclerotic cardiovascular disease (ASCVD). Comprehensive comparisons of the efficacy, safety, and cost-effectiveness across different PCSK9 inhibitors remain limited, and current evidence requires updating. To address this gap, this study applies a health technology assessment framework to systematically evaluate the use of PCSK9 inhibitors in patients with ASCVD. Methods: A systematic search of PubMed, EMBASE, and the Cochrane Library was conducted from database inception to February 28, 2026 to identify randomized controlled trials (RCTs) comparing PCSK9 inhibitors with standard care (statins with or without ezetimibe) in patients with ASCVD. Both pairwise and network meta-analyses were applied to synthesize direct and indirect evidence. Trial sequential analysis (TSA) was performed to evaluate the sufficiency of the accumulated data. In addition, a Markov model was developed from the perspective of the Chinese healthcare system to assess the cost-effectiveness of PCSK9 inhibitors in ASCVD patients. Results: In total, 24 RCTs comprising 63,328 participants were included. The results of TSA and network meta-analysis showed that, compared with SOC, all three PCSK9 inhibitors significantly reduced LDL-C levels. No statistically significant differences were found for stroke outcomes. However, both alirocumab and evolocumab significantly reduced the risk of non-fatal myocardial infarction. None of the three PCSK9 inhibitors was associated with an increased risk of serious adverse events. Using the meta-analysis findings and data from the Chinese healthcare system, the incremental cost-effectiveness ratios (ICERs) for alirocumab, evolocumab, and inclisiran versus standard care were estimated at USD 12,791.07/QALY, USD 11,646.38/QALY, and USD 31,730.14/QALY, respectively. In a scenario analysis incorporating a 72.1% reduction in the price of inclisiran, its ICER decreased to USD 9,686.31/QALY. The one-way sensitivity analysis showed that the discount rate exerted the greatest influence on model outcomes. In the price-reduction scenario, probabilistic sensitivity analysis indicated that inclisiran had a 96.6% probability of being cost-effective at a willingness-to-pay threshold of USD 13,410/QALY. Conclusion: Currently, evolocumab demonstrates relative advantages in lipid-lowering efficacy, cardiovascular outcomes, and economic value for patients with ASCVD. Alirocumab represented a cost-effective alternative. In the scenario analysis incorporating a 72.1% reduction in the price of inclisiran, inclisiran became a potentially highly cost-effective option in the Chinese healthcare setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纯情的阁发布了新的文献求助10
刚刚
刚刚
纯情的阁发布了新的文献求助10
1秒前
纯情的阁发布了新的文献求助10
1秒前
1秒前
h11的应助被Prof.Z采纳,获得30
1秒前
Owen的应助被万寿宫人采纳,获得30
3秒前
1342314123完成签到,获得积分10
3秒前
胖大海完成签到 ,获得积分10
3秒前
纯情的阁发布了新的文献求助10
3秒前
纯情的阁发布了新的文献求助10
3秒前
3秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
aylwtt完成签到,获得积分10
4秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
高高发布了新的文献求助10
4秒前
纯情的阁发布了新的文献求助10
4秒前
4秒前
高高发布了新的文献求助10
4秒前
4秒前
高高发布了新的文献求助10
5秒前
高高发布了新的文献求助10
5秒前
隐形的妙松完成签到,获得积分10
5秒前
高高发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
6秒前
6秒前
纯情的阁发布了新的文献求助10
7秒前
纯情的阁发布了新的文献求助10
7秒前
纯情的阁发布了新的文献求助10
7秒前
纯情的阁发布了新的文献求助10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554315
关于积分的说明 21718840
捐赠科研通 7747967
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551811
邀请新用户注册赠送积分活动 2471239